SAN DIEGO, Aug. 31 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL - News) announced today that a “prime-boost” vaccine regimen tested in 40 HIV-uninfected subjects in a National Institutes of Health (NIH) sponsored Phase 1 clinical trial was safe and well-tolerated, and was highly effective in inducing T-cell immune responses with multiple functions that may be important for controlling HIV infection. The trial involved priming an immune response with three doses of a plasmid DNA vaccine, based on Vical’s proprietary DNA delivery technology, and boosting the response with a single dose of adenoviral vector vaccine given at a later date.
“We are encouraged that the prime-boost vaccine regimen in this trial was highly effective in generating multiple types of HIV-specific T-cell immune responses, representing another logical step toward development of an effective HIV vaccine,” said Vijay B. Samant, Vical’s President and Chief Executive Officer.
The vaccine was developed by scientists at the Dale and Betty Bumpers Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and was manufactured by Vical. The vaccine incorporates HIV genetic material from the three most globally important HIV subtypes, clades A, B and C, which are involved in about 85 percent of all HIV infections around the world. The same prime-boost vaccine combination is being tested in 480 HIV-uninfected subjects through a multinational Phase 2 trial initiated in October 2005. The combination also is being tested in 15 HIV-infected subjects receiving highly active antiretroviral therapy (HAART) through a Phase 1 trial initiated in August 2006. A larger multinational Phase 2 trial in several thousand HIV-uninfected subjects is expected to begin in early 2007.
The vaccine used in the Phase 1 trial incorporates parts of four HIV genes. Three of these vaccine components are modified versions of HIV genes called gag, pol and nef, synthetically made based on sequence from clade B, the subtype that predominates in Europe and North America. The fourth vaccine component is a modified version of the HIV gene named env. The env gene codes for a protein on the outer coat of the virus that allows it to recognize and attach to human cells. VRC scientists were the first to combine modified env from clades A and C, which are the most common in Africa and parts of Asia, with the modified env gene from clade B. The study was conducted at the NIH Clinical Center.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected, including: whether VRC and the NIH Clinical Center will complete the ongoing trials and initiate additional trials as planned; whether the HIV vaccine or any other product candidates will be shown to be safe and effective in clinical trials; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company’s filings with the Securities and Exchange Commission. These forward-looking statements represent the company’s judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.
Contacts: Investors: Media: Alan R. Engbring Susan Neath Vical Incorporated Porter Novelli Life Sciences (858) 646-1127 (619) 849-6007 Website: www.vical.com
Source: Vical Incorporated
